ClinicalTrials.gg
CompletedNCT06111092Updated Nov 5, 2026Results posted

Testing Design Thinking Methodology to Engage Hispanic and Latino Families of Autistic Children in Research.

An interventional study of Design Thinking and Focus Groups in Autism Spectrum Disorder and Patient Engagement, sponsored by Thomas Jefferson University. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Primary conditionAutistic DisorderRegistry: Autism Spectrum DisorderReclassifiedWhy we changed it
Registry
Autism Spectrum Disorder — the first condition term the registry derived for this study.
ClinicalTrials.gg
Autistic Disorder
Why
  1. The study's listed conditions name Autistic Disorder, a narrower term within Autism Spectrum Disorder.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Thomas Jefferson University · Not applicable, Interventional, and Other

How we know

Updated Nov 5, 2026Now CompletedResults posted+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 604 studies in Autistic Disorder with a site in United States — 123 open to participants now, 152 under way, 3 of them phase 3. Autistic Disorder · United States.

Enrollment
90th of 505
130 · median 44
Started
2024
with 30 others
No phase
296 of 604
83 open now
Registered
488th of 604
by date

Among the 604 studies in Autistic Disorder with a site in United States, this one is the 90th largest by enrollment of the 505 interventional ones that give a count, is one of 31 that started in 2024, is one of 296 with no phase, and was the 488th registered.

Autistic Disorder

1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

123 of the 604 studies in Autistic Disorder with a site in United States are open now. Recruiting first, the newest first:

118 more — sign in →

All 123 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 184 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 144 (78%) stop at 75 or younger; 150 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 604 studies in Autistic Disorder with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to compare two methods of engagement in research that include autistic individuals, Hispanic and Latino parents of autistic children, occupational therapy clinicians, teachers, and to use the information collected in the sessions to culturally adapt the occupational therapy Ayres Sensory Integration intervention to improve participation and health outcomes.

The main questions it aims to answer are:

Does the Design Thinking process result in higher stakeholder engagement and satisfaction in the research process in comparison to Focus Groups? Secondary question: Do cultural adaptations using DT data yield higher acceptability and implementation feasibility scores than FG methods?

Participants will:

  • Be randomized into two groups of engagement (focus groups and design thinking)
  • Be blinded (clinicians, selected caregivers, autistic persons, and cultural experts) and will rate the culturally adapted manualized protocol and evaluate the acceptability, feasibility, and cultural appropriateness of each protocol based on DT data, higher than the protocol based on FG data.
Read the detailed description

Racial and ethnic minorities with autistic children experience delays in access to therapy services that can result in poorer outcomes, decreased quality of life, and increased parental and financial stress. Many autism interventions were developed and tested with only White participants, assuming they could be transferable to minority populations. However, research has found that this is not the case and that interventions that are not adapted to an individual's culture and ethnicity do not work as well and are not used as frequently. In this project, we compare two methods of stakeholder engagement, Design Thinking (DT) and Focus Groups (FG), to determine which is better at getting input on the facilitators and barriers to access therapy for autistic children. We focus on Hispanics and Latinos as this is the largest minority group in the US, with one of the fastest-growing groups of autistic children. Our long-term objective is to improve the functional skills and health of Hispanic/Latino autistic children and their families by improving access to an occupational therapy intervention designed to improve daily living skills, socialization, and quality of life. Occupational therapy using Ayres Sensory Integration (OT/ASI) is the only evidence-based intervention that addresses the sensory symptoms in autism. We will use input from these engagement sessions to adapt two versions of the OT/ASI manual: one using DT data and the other using FG data. Outcomes are evaluated following each step. Following the completion of this project, the planned outputs of the study are data on the most effective minority stakeholder engagement method and a culturally adapted OT/ASI manual for Hispanic and Latino autistic children for clinicians and researchers. This information can support future researchers who are engaging Hispanic/Latino individuals or other minority groups in research.

Methods: A randomized mixed methods design is used to evaluate stakeholder engagement methods. Phase one will compare two stakeholder engagement methods (Design Thinking -DT, and Focus Group - FG) and evaluate stakeholder engagement based on the PCORI areas of stakeholder engagement which are operationalized in the Stakeholder-Centric Engagement Evaluation and qualitative data. Phase two utilizes data from phase one to culturally adapt the intervention (two separate intervention protocols will be adapted - one based on FG data and another based on DT data as described below), and obtain stakeholder input on acceptability and feasibility for the Hispanic/Latino autistic population. This provides a second way to measure the effectiveness of each stakeholder engagement method as we will have data to indicate which method (DT or FG) resulted in the highest-rated protocol. The data provided by this study will be used as a basis for a later comparative effectiveness study that will study the culturally adapted protocol's outcomes.

All sessions will be held in Spanish and/or English based on the groups' preferences. Since our intent is to hear the voices of Hispanic/Latino stakeholders, it seems valuable to hold focus groups in Spanish when the participants are Spanish as first language speakers (hereafter referred to as Spanish-first) with audio recordings and later transcription into English for analysis. To accommodate those who prefer English, we will make every effort to group these participants together. When, and if, the Spanish-first groups include participants who prefer English, we will have a Spanish to English translator available. In other words, we will be respectful of each participant's language to optimize their comfort in the engagement sessions.

This project addresses an urgent need to engage stakeholders as part of the research process from conceptualization to dissemination and the need for culturally sensitive evidence-based interventions for Hispanic/Latino autistic children. This project is being developed by a skilled and experienced team of investigators.

03

Conditions studied

  • Autism Spectrum Disorder
  • Patient Engagement

Browse trials for

Keywords

  • Autism
  • Patient engagement
04

In context

Autistic Disorder Reclassified

1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.

This study's enrollment of 130 is above the median of 50 across 814 interventional studies indexed under Autistic Disorder.

Browse Autistic Disorder studies →

Lead sponsor

Thomas Jefferson University is the lead sponsor of 394 studies on the registry; 69 are open to participants now.

Of its 45 completed or terminated interventional studies of FDA-regulated products, 21 (47%) have results posted.

Compared within Autistic Disorder, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autism Spectrum Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Autistic person:

    • confirmed diagnosis of autism spectrum disorder
    • Hispanic/Latino
    • received therapeutic services as a child; and
    • willing and able (with i.e., language and cognitive skills) to participate in the design thinking or focus group session designed to learn about the facilitator and barriers to receipt of therapeutic services.
  • Parent/caregiver:

    • Hispanic/Latino caregiver of an autistic child who receives or received therapeutic services such as occupational, physical, speech and language therapy
    • willing to participate in the design thinking or focus group session designed to learn about the facilitator and barriers to receipt of therapeutic services.

Exclusion criteria

  • Do not meet age for autistic individual or diagnostic criteria
06

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
130 participants (actual)

Study arms

  • Other
    Design Thinking Group

    A group of randomized participants (autistic adults, parents/caregivers, OT practitioners, teachers, and cultural experts) will participate in the Design Thinking (DT) process.

    Other: Design Thinking

  • Other
    Focus Group

    A group of randomized participants (autistic adults, parents/caregivers, OT practitioners, teachers, and cultural experts) will participate in the Focus Group (FG) process.

    Other: Focus Groups

Interventions

  • OtherDesign Thinking

    Participants attend the DT session through all the stages that include emphasize, define, ideate, prototype and test.

  • OtherFocus Groups

    Participants attend the FG that includes the introduction. discussion, and reflection.

07

What researchers measure

Primary outcomes

  1. Stakeholder-Centric Engagement Evaluation (S-CEE) (Martinez et al., 2021)

    The Stakeholder-Centric Engagement Evaluation (S-CEE) is a measure used to assess the frequency and perceived quality of stakeholder engagement across 10 engagement domains, including: collaboration, communication, inclusion, transparency, learning, organizational structure, dissemination, and responsiveness to input. The measure evaluates two dimensions of engagement: frequency ("How Often") and quality ("How Well"). Each item is rated using a 5-point Likert scale. For "How Often," response options range from 1 ("Never") to 5 ("Always"). For "How Well," response options range from 1 ("Poor") to 5 ("Excellent"). Higher scores indicate greater frequency and higher perceived quality of stakeholder engagement. The S-CEE was administered to all participants immediately following the one-time engagement session to capture their perceptions of engagement.

    Time frame: Immediately following the one time engagement session

Secondary outcomes

  1. Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM) and the Feasibility of Intervention Measure (FIM) (Weiner et al., 2017)

    The Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and Feasibility of Intervention Measure (FIM) are validated implementation outcome measures used to assess acceptability, appropriateness, and feasibility of the culturally adapted intervention based on the discussions in the focus groups and design thinking engagement sessions to improve access, use of therapy services, and strategies to adapt an evidence-based therapy intervention. AIM includes 5 items assessing the perceived acceptability of the intervention, IAM includes 4 items assessing the perceived appropriateness or fit of the intervention, and FIM includes 4 items assessing the perceived feasibility of implementing the intervention. Each item is rated using a 5-point Likert scale ranging from 1 ("Completely disagree") to 5 ("Completely agree"). Higher scores indicate greater perceived acceptability, appropriateness, and feasibility of the culturally adapted intervention.

    Time frame: Immediately following the cultural adaptation reviews.

08

Results

Posted Nov 5, 2026
Limitations and caveats
No major limitations or caveats were identified that would affect the interpretation of the study findings.

Participant flow

Recruitment occurred between February 2024 and September 2025 across Pennsylvania, New Jersey, and Delaware. A community-based, multimodal recruitment strategy was implemented to engage Hispanic/Latino (H/L) autistic adults and parents/caregivers of autistic children, occupational therapists, and teachers, through broad dissemination and relationship-centered outreach. Strategies included distributing bilingual flyers in community settings and outreach to organizations.

Participant flow — Overall Study
MilestoneDesign ThinkingFocus Groups
Started6763
Autistic adults35
Parents/caregivers4235
Teachers1419
Occupational therapists84
Completed6763
Not completed00

Outcome measures

PrimaryStakeholder-Centric Engagement Evaluation (S-CEE) (Martinez et al., 2021)

The Stakeholder-Centric Engagement Evaluation (S-CEE) is a measure used to assess the frequency and perceived quality of stakeholder engagement across 10 engagement domains, including: collaboration, communication, inclusion, transparency, learning, organizational structure, dissemination, and responsiveness to input. The measure evaluates two dimensions of engagement: frequency ("How Often") and quality ("How Well"). Each item is rated using a 5-point Likert scale. For "How Often," response options range from 1 ("Never") to 5 ("Always"). For "How Well," response options range from 1 ("Poor") to 5 ("Excellent"). Higher scores indicate greater frequency and higher perceived quality of stakeholder engagement. The S-CEE was administered to all participants immediately following the one-time engagement session to capture their perceptions of engagement.

Time frame:
Immediately following the one time engagement session
Reported as:
Mean · Units on a scale
Stakeholder-Centric Engagement Evaluation (S-CEE) (Martinez et al., 2021)
Units on a scaleDesign ThinkingFocus Groups
How Often- Area 1 Issues Important to the Hispanic/Latino population4.4 ± 0.64.3 ± 0.6
How Often-Area 2 Respect and value group member perspectives4.8 ± 0.44.9 ± 0.2
How often- Area 3 Seek group members input4.8 ± 0.44.6 ± 0.6
How often-Area 4 Act on group members input4.7 ± 0.54.4 ± 0.7
How often- Area 5 Mutual learning between group members and research team4.8 ± 0.44.6 ± 0.4
How Often- Area 6 Deal with conflict and disagreements effectively4.8 ± 0.44.8 ± 0.3
How often- Area 7 Communicate with group members using effective methods4.7 ± 0.54.7 ± 0.3
How often- Area 8 Use a clear organizational structure4.8 ± 0.44.8 ± 0.4
How often-Area 9 Be transparent and informative4.6 ± 0.64.6 ± 0.6
How often- Area 10 Involve the group members in dissemination activities4.5 ± 0.84.5 ± 0.9
How well- Area 1 Issues Important to H/L population4.2 ± 0.94.2 ± 0.8
How Well- Area 2 Respect and value group member perspectives4.8 ± 0.54.8 ± 0.3
How well- Area 3 Seek group members input4.8 ± 0.54.7 ± 0.5
How well- Area 4 Act on group members input4.7 ± 0.54.4 ± 0.7
How well-Area 5 Mutual learning between group members and research team4.8 ± 0.44.6 ± 0.5
How well-Area 6 Deal with conflict and disagreements effectively4.7 ± 0.44.7 ± 0.4
How well- Area 7 Communicate with group members using effective methods4.7 ± 0.44.7 ± 0.4
How well-Area 8 Use a clear organizational structure4.8 ± 0.54.8 ± 0.4
How well- Area 9 Be transparent and informative4.5 ± 0.74.7 ± 0.6
How well- Area 10 Involve the group members in dissemination activities4.5 ± 0.94.6 ± 0.8
SecondaryAcceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM) and the Feasibility of Intervention Measure (FIM) (Weiner et al., 2017)

The Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and Feasibility of Intervention Measure (FIM) are validated implementation outcome measures used to assess acceptability, appropriateness, and feasibility of the culturally adapted intervention based on the discussions in the focus groups and design thinking engagement sessions to improve access, use of therapy services, and strategies to adapt an evidence-based therapy intervention. AIM includes 5 items assessing the perceived acceptability of the intervention, IAM includes 4 items assessing the perceived appropriateness or fit of the intervention, and FIM includes 4 items assessing the perceived feasibility of implementing the intervention. Each item is rated using a 5-point Likert scale ranging from 1 ("Completely disagree") to 5 ("Completely agree"). Higher scores indicate greater perceived acceptability, appropriateness, and feasibility of the culturally adapted intervention.

Time frame:
Immediately following the cultural adaptation reviews.
Reported as:
Mean · units on a scale
Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM) and the Feasibility of Intervention Measure (FIM) (Weiner et al., 2017)
units on a scaleDesign ThinkingFocus Groups
Acceptability of Intervention Measure (AIM)4.45 ± 0.654.42 ± 0.65
Intervention Appropriateness Measure (IAM)4.38 ± 0.664.35 ± 0.64
Feasibility of Intervention Measure (FIM)4.41 ± 0.674.33 ± 0.65

Adverse events

Collected over During the assigned Design Thinking or Focus Group engagement session, a one-time session lasting an average of 3 hours.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Design Thinking0/67 (0%)0/67 (0%)0/67 (0%)
Focus Groups0/63 (0%)0/63 (0%)0/63 (0%)

Baseline characteristics

The number of participants for each arm is correct.

Age, Continuous
Age, Continuous(years)Design ThinkingFocus GroupsTotal
Mean39.9 ± 11.140.8 ± 11.240.3 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Design ThinkingFocus GroupsTotal
Female5554109
Male12921
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Design ThinkingFocus GroupsTotal
American Indian or Alaska Native235
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American516
White191332
More than one race347
Unknown or Not Reported374279
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Design ThinkingFocus GroupsTotal
Hispanic or Latino5352105
Not Hispanic or Latino141125
Unknown or Not Reported000
09

Study locations

1 site
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107-5084, United States
10

References and documents

Publications

  • Rios-Vega L, Rising K, Fields M, Freedman B, Toole N, Ramos J, Schaaf R. Engaging Diverse Stakeholders to Improve Therapy Access for Hispanic and Latino Autistic Individuals and Families. Am J Occup Ther. 2025 Mar 1;79(2):7902180150. doi: 10.5014/ajot.2025.050942. PubMed 39970258 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Publications in high-impact autism and occupational therapy journals and presentations at national and international autism research meetings.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Some de-identified data will be available following completion of the study and publication of findings.

Access criteria: Upon written request (reviewed by the principal investigator) information will be shared.

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Apr 2026, 26 months.

Results were first posted in Nov 2026, 7 months after primary completion.

Of 355 non-industry interventional studies with no phase under Autistic Disorder, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's 26 months is close to that.

Counting every sponsor, half of 367 studies reached it within 26 months; a quarter within 13 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Jul 2026 → Apr 2026 and completion Nov 2026 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2023
First posted
Nov 1, 2023
StartActual
Feb 1, 2024
Primary completionActual
Apr 1, 2026was Jul 2026
CompletionActual
Apr 1, 2026was Nov 2026
Results first posted
Nov 5, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Nov 5, 2026
Results
Results posted
posted Nov 5, 2026
Sites
1 site added — first site in United States
Show site
  • Thomas Jefferson University · Philadelphia, United States
Nov 5, 2026
Primary completion
Jul 31, 2026→Apr 1, 2026 (actual)
Nov 5, 2026
Study completion
Nov 30, 2026→Apr 1, 2026 (actual)
Nov 5, 2026
Enrollment
186 (estimated)→130 (actual)
Nov 5, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Stakeholder-Centric Engagement EvaluationNow Stakeholder-Centric Engagement Evaluation (S-CEE) (Martinez et al., 2021)Time frame: up to 14 weeks → Immediately following the one time engagement session
Nov 5, 2026
Publications
Results publication added: Rios-Vega L, Rising K, Fields M, Freedman B, Toole N, Ramos J, Schaaf R. Engaging Diverse Stakeholders to Improve Therapy Access for Hispanic and Latino Autist… PubMed 39970258 ↗
Nov 5, 2026
Secondary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameAcceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM) and the Feasibility of Intervention Measure (FIM) (Weiner et al., 2017)up to 14 weeks → Immediately following the cultural adaptation reviews.
  • DescriptionAcceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM) and the Feasibility of Intervention Measure (FIM) (Weiner et al., 2017): how it is measured was reworded
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Not yet recruiting→Completed
    Results posted
    Publications Results publication added: Rios-Vega L, Rising K, Fields M, Freedman B, Toole N, Ramos J, Schaaf R. Engaging Diverse Stakeholders to Improve Therapy Access for Hispanic and Latino Autist… PubMed 39970258 ↗
    1 site added — first site in United States
    Show site
    • Thomas Jefferson University · Philadelphia, United States
    Primary completion Jul 31, 2026→Apr 1, 2026 (now actual)
    Study completion Nov 30, 2026→Apr 1, 2026 (now actual)
    Enrollment 186 (estimated)→130 (actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Stakeholder-Centric Engagement EvaluationNow Stakeholder-Centric Engagement Evaluation (S-CEE) (Martinez et al., 2021)Time frame: up to 14 weeks → Immediately following the one time engagement session
    Secondary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameAcceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM) and the Feasibility of Intervention Measure (FIM) (Weiner et al., 2017)up to 14 weeks → Immediately following the cultural adaptation reviews.
    • DescriptionAcceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM) and the Feasibility of Intervention Measure (FIM) (Weiner et al., 2017): how it is measured was reworded
    + 5 other changes: verification date, description, contact details, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT06111092
Collaborators
Patient-Centered Outcomes Research Institute
Responsible party
Sponsor
First posted
Nov 1, 2023
Start date
Feb 1, 2024
Primary completion
Apr 1, 2026
Completion
Apr 1, 2026
Results posted
Nov 5, 2026
Last update
Nov 5, 2026

Study contacts

Roseann C Schaaf
principal investigator · Thomas Jefferson University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion